Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (PACB)
NASDAQ:PACB
Pacific Biosciences (PACB) Stock Price & Analysis
2,098 Followers
PACB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $14.55
Previous Close$1.46
Volume18.74M
Average Volume (3M)9.63M
Market Cap
$397.53M
Enterprise Value$565.30M
Total Cash (Recent Filing)$767.79M
Total Debt (Recent Filing)$935.56M
Price to Earnings (P/E)-1.2
Beta3.10
Next Earnings
May 02, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.21
Shares Outstanding267,951,880
10 Day Avg. Volume15,277,090
30 Day Avg. Volume9,628,171
Standard Deviation0.24
R-Squared0.16
Alpha-0.00547
Financial Highlights & Ratios
Price to Book (P/B)-1.72
Price to Sales (P/S)2.92
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.71
Enterprise Value/Gross Profit11.53
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$5.86Price Target Upside301.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Pacific Biosciences News
Bulls Say, Bears Say
Bulls Say
Financial PerformancePacific Biosciences reported a strong year-over-year revenue growth, which reflects the company's commercial success and potential for expansion.
Market OpportunityAnalysts' diligence supports a strong shift to long reads and Revio traction, suggesting a multi-year growth opportunity.
Product DemandManagement plans on focusing on increasing Revio adoption by converting current customers and gaining new ones, with a notable percentage of systems ordered by new customers.
Bears Say
Company OutlookSensitivity to the capital equipment funding environment and lack of visibility on customer spending could raise concerns about future revenue streams and profitability.
Financial PerformancePreliminary 1Q24 results of $38.8mn in revenue were below estimates of $50.6mn, indicating the company may be facing headwinds in generating sales.
Market Expectations2024 revenue guidance is approximately 6% below consensus, suggesting the company could underperform in a challenging capital expenditure environment.
---
Ownership Overview
3.91% Insiders
25.73% Mutual Funds
39.57% Other Institutional Investors
30.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PACB FAQ
What was Pacific Biosciences’s price range in the past 12 months?
Pacific Biosciences lowest stock price was $1.25 and its highest was $14.55 in the past 12 months.
What is Pacific Biosciences’s market cap?
Currently, no data Available
When is Pacific Biosciences’s upcoming earnings report date?
Pacific Biosciences’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were Pacific Biosciences’s earnings last quarter?
Pacific Biosciences released its earnings results on Feb 15, 2024. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.287 by -$0.023.
Is Pacific Biosciences overvalued?
According to Wall Street analysts Pacific Biosciences’s price is currently Undervalued.
Does Pacific Biosciences pay dividends?
Pacific Biosciences does not currently pay dividends.
What is Pacific Biosciences’s EPS estimate?
Pacific Biosciences’s EPS estimate is -$0.28.
How many shares outstanding does Pacific Biosciences have?
Pacific Biosciences has 272,279,900 shares outstanding.
What happened to Pacific Biosciences’s price movement after its last earnings report?
Pacific Biosciences reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.287. Following the earnings report the stock price went down -13.943%.
Which hedge fund is a major shareholder of Pacific Biosciences?
Among the largest hedge funds holding Pacific Biosciences’s share is ARK Investment Management LLC. It holds Pacific Biosciences’s shares valued at 338M.
---
Pacific Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.86 (301.37% Upside)
$5.86 (301.37% Upside)
Blogger Sentiment
Bullish
PACB Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $327.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.28%
12-Months-Change
Fundamentals
Return on Equity
-48.53%
Trailing 12-Months
Asset Growth
-1.19%
Trailing 12-Months
Company Description
Pacific Biosciences
Pacific Biosciences of California, Inc. engages in the development, manufacture and sale of an integrated platform for genetic analysis. Its products and services include PacBio sequel system, consumables, analytical software, and single molecule real-time (SMRT) compatible products. It operates through the following geographical segments: North America, Europe, and Asia Pacific. The company was founded by Stephen Turner and Joseph Vincent Bonventre on July 14, 2000 and is headquartered in Menlo Park, CA.
---
PACB Earnings Call
Q4 2024
0:00 / 0:00
---
PACB Stock 12 Months Forecast
Average Price Target
$5.86
▲(301.37% Upside)
Technical Analysis
Best Analysts Covering PACB
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
+12.78%
reiterated a buy rating 4 days ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +12.78% per trade.
---